CJC-1295 research guide for Frévent. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers trying to source CJC-1295 in Frévent quickly find that local retail options are virtually absent. What this means for Frévent researchers is that geography is secondary to your ability to verify analytical documentation — and those verification methods are available to every researcher. A credible CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. This guide walks Frévent researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
The Science Behind CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Frévent comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
The most effective path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums maintain informal vendor reputation databases that are more trustworthy than marketing materials. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. For Frévent researchers evaluating new suppliers: a modest first purchase to test the product before scaling up your order is what experienced peptide researchers consistently do. For Frévent researchers making a first CJC-1295 purchase: verify the vendor against this framework, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Frévent
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; avoid repeatedly thawing and refreezing reconstituted peptide by dividing into single-dose aliquots before freezing. Quality CJC-1295 sourcing is not separable from research safety — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that rigorous vendor evaluation eliminates. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not approved for human use and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
